Participated · Equity · Feb 2024

Sencure has developed an ultra-low-power biometric sensing chip and a library of signal-processing algorithms for medical monitoring and diagnostics, which it can license as IP. The chip targets wearable biometric solutions across cardiac monitoring, COPD, children’s asthma, neurological cases, EEG recordings, ICU-grade ventilation, vital-sign monitoring, COVID-19 symptom monitoring, athletic training/rehabilitation, and general stress/activity tracking. The technology reflects five years of R&D and is described by the company and investors as outperforming current medical chips on price and quality, with competitive advantages in much lower power consumption and smaller size. Sencure also develops textile-integrated medical wearables aimed at maximizing patient comfort in real-life monitoring situations. The company plans to use new financing to file patent applications, continue product development, and execute a global rollout. The financing round comprises a €1.0M investment from Cottonwood Technology Fund and €0.5M from co-investor Lumana Invest (totaling €1.5M). The article positions Sencure to participate in the growing medical-wearables market, which is projected to expand significantly by 2025. Sencure, based in Enschede, Netherlands, develops chips for medical wearable biosensors with a focus on remote patient monitoring. Its flagship SNCE-800 microprocessor is designed to capture high-quality electrophysiological signals such as ECG and EEG while consuming minimal power. The company says the chip enables smaller, more comfortable devices, extended battery life and faster medical-device development. Founded in 2021, Sencure originates from ItoM Medical BV, the 2018-founded medical branch of Semiconductor Ideas to the Market (ItoM) BV. Its products are used to measure a range of bioelectrical data including cardiac, respiratory and brain activity. Sencure says it will use the new funding to accelerate industrialisation of the SNCE-800 and bring biosensor solutions to market faster.

Participated · Series B · Nov 2021

Neuroplast develops Neuro-Cells®, an autologous treatment manufactured from a patient’s own bone marrow‑derived hematopoietic and mesenchymal stem cells designed to act in the acute phase after traumatic spinal cord injury (TSCI). The company completed a Phase I clinical trial that confirmed safety and tolerability without product‑related adverse events and is preparing an international multicenter randomized placebo‑controlled Phase II study. Neuroplast holds a GMP license and has received a European Orphan Designation to enable fast‑track development toward conditional EMA approval. The Series B funding will support running Phase II and III trials, consulting with the EMA and executing a Health Technology Assessment. Neuroplast was founded in August 2014 and is based at Brightlands Chemelot Campus in the Netherlands. The company plans to explore broader applicability of the Neuro-Cells® platform to other primarily inflammation‑driven neurological disorders and is seeking complementary investment for those activities.

Participated · Equity · Sep 2020

VIVOLTA develops and manufactures electrospun medical products and operates as a contract development and manufacturing organization (CDMO) for clients. It uses a proprietary, fully automated MediSpin™ production platform—described in the article as the world’s first—to enable high-throughput manufacturing of tubular electrospun products such as vascular stent grafts and prosthetic heart valves. In 2021 the company transitioned from an equipment manufacturer (formerly IME) into a CDMO and has secured development partnerships with leading medical device manufacturers and startups. VIVOLTA is concentrating on near-term application areas including cardiovascular medicine, soft tissue repair and reconstruction, orthopaedic sports medicine, and advanced drug delivery systems. The new funding is intended to strengthen application development, engineering, commercial support, quality, regulatory, and manufacturing capabilities and to expand ISO class 7 production area footprint in preparation for clinical and commercial launches over the coming three years. Shareholders named in the article include TIIN Capital, Lumana Invest, Borski Fund, and Brabantse Ontwikkelings Maatschappij. IME Medical Electrospinning develops electrospun, fiber-based medical device solutions that mimic the human extracellular matrix in nanometer and micrometer format for implants and membranes. The company applies specific polymers to produce scaffolds used in heart valves, blood vessels, nerves, tendons, skin and bone repair. Its MediSpin™ XL platform was developed for MedTech industrial manufacturing and ensures firm control of critical electrospinning parameters, producing identical and consistent end-products. The MediSpin XL platform is now also suitable for pharmaceutical drug-delivery applications. Customers and scientific partners include the MedTech and Pharma industry, scientists and health institutions. The business is led by Managing Directors Ramon Solberg and Judith Heikoop.